NZ553914A - Stable liquid formulations of plasmid DNA at low buffer concentration - Google Patents

Stable liquid formulations of plasmid DNA at low buffer concentration


Publication number
NZ553914A NZ553914A NZ55391405A NZ553914A NZ 553914 A NZ553914 A NZ 553914A NZ 553914 A NZ553914 A NZ 553914A NZ 55391405 A NZ55391405 A NZ 55391405A NZ 553914 A NZ553914 A NZ 553914A
New Zealand
Prior art keywords
plasmid dna
liquid formulations
stable liquid
buffer concentration
low buffer
Prior art date
Application number
Francis Blanche
Michel Couder
Nicolas Maestrali
Thierry Guillemin
David Gaillac
Original Assignee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PCT/EP2004/011437 priority Critical patent/WO2005026331A2/en
Priority to PCT/EP2005/005213 priority patent/WO2005100542A1/en
Application filed by Centelion filed Critical Centelion
Priority to PCT/EP2005/010881 priority patent/WO2006029908A1/en
Publication of NZ553914A publication Critical patent/NZ553914A/en



    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • C12N15/68Stabilisation of the vector


Disclosed is a stable plasmid DNA liquid storage composition comprising a purified plasmid DNA and a buffer solution, wherein the buffer is present at a concentration of less than 2 mM to maintain the pH of said composition between 6 and 9, wherein the composition comprises predominantly supercoiled form of plasmid DNA, and wherein the plasmid DNA is stable at temperatures around 4°C to 25°C.
NZ553914A 2003-09-17 2005-09-19 Stable liquid formulations of plasmid DNA at low buffer concentration NZ553914A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/EP2004/011437 WO2005026331A2 (en) 2003-09-17 2004-09-17 Method of preparation of pharmaceutically grade plasmid dna
PCT/EP2005/005213 WO2005100542A1 (en) 2004-04-19 2005-04-19 Method for purifying plasmid dna
PCT/EP2005/010881 WO2006029908A1 (en) 2004-09-17 2005-09-19 Stable liquid formulations of plasmid dna

Publications (1)

Publication Number Publication Date
NZ553914A true NZ553914A (en) 2009-11-27



Family Applications (1)

Application Number Title Priority Date Filing Date
NZ553914A NZ553914A (en) 2003-09-17 2005-09-19 Stable liquid formulations of plasmid DNA at low buffer concentration

Country Status (14)

Country Link
EP (1) EP1791945A1 (en)
JP (1) JP2008512997A (en)
KR (1) KR20070058621A (en)
CN (1) CN101040041A (en)
AU (1) AU2005284244A1 (en)
BR (1) BRPI0515553A (en)
CA (1) CA2579340A1 (en)
EA (1) EA011554B1 (en)
IL (1) IL181753D0 (en)
MX (1) MX2007003214A (en)
NO (1) NO20071946L (en)
NZ (1) NZ553914A (en)
TN (1) TNSN07087A1 (en)
WO (1) WO2006029908A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2542385C2 (en) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Method for preparing pharmaceutical composition for inducing angiogenesis in tissues, pharmaceutical composition prepared by this method, and method of treating individual's tissue and/or organ ischemia
CN104032005B (en) * 2014-06-12 2015-11-25 成都中创清科医学检验所有限公司 Save method of preservation agents and intermediates sequencing pcr
CN107208094A (en) * 2014-12-29 2017-09-26 株式会社博纳克 Composition containing nucleic acid molecule stably
RU2612497C2 (en) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Optimized nucleotide sequence and pharmaceutical compositions based thereon with sustained vegf transgene expression
RU2628087C1 (en) * 2016-09-01 2017-08-14 Игорь Валериевич Корниенко Composition with antimicrobial action for storage of dna or dna-containing preparations (versions) and its application
CN106554956A (en) * 2016-12-07 2017-04-05 安徽智飞龙科马生物制药有限公司 Industrialized preparation method for BCG-CpG-DNA
WO2019037828A1 (en) * 2017-08-25 2019-02-28 Zoetis Services Llc A nucleic acid probe, a method of immobilizing the nucleic acid to a solid support using uv light, a solid support comprising an immobilized nucleic acid probes, and a test device comprising a solid support

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
FR2773818B1 (en) * 1998-01-21 2000-02-18 Pasteur Merieux Serums Vacc Method and bacteria lysis device
EP1242441A4 (en) * 1999-12-17 2004-04-14 Merck & Co Inc Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef

Also Published As

Publication number Publication date
EA011554B1 (en) 2009-04-28
WO2006029908A1 (en) 2006-03-23
NO20071946L (en) 2007-05-29
AU2005284244A1 (en) 2006-03-23
MX2007003214A (en) 2007-10-11
JP2008512997A (en) 2008-05-01
TNSN07087A1 (en) 2008-06-02
KR20070058621A (en) 2007-06-08
EA200700656A1 (en) 2007-10-26
CA2579340A1 (en) 2006-03-23
EP1791945A1 (en) 2007-06-06
BRPI0515553A (en) 2008-07-29
CN101040041A (en) 2007-09-19
IL181753D0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
JO2475B1 (en) Glucokinase Activators
TWI415840B (en) Novel compounds and compositions and methods of use
WO2002000904A3 (en) Recombinant constructs and their use in reducing gene expression
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA03011972A (en) Arylamines for the treatment of conditions associated with gsk-3.
NO20044822L (en) Thickened acidic composition and uses thereof
NZ551017A (en) Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors
EG23719A (en) New process for the synthesis of (I S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane and addition salts thereof, and application in the synthesis of I V abradine and addition salts thereof witha pharmaceutically acceptable acid
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TW200533663A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
IL177324A (en) Composition comprising proliferating primate pluripotent stem cells
EP1595936A4 (en) Antioxidative composition and composition for external use
ES2188607T3 (en) enzyme compositions stabilized liquids.
EP2298903A3 (en) Alpha-amylase mutants with altered properties
WO2006106423A8 (en) Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
MXPA03003749A (en) Herbicide-tolerant plants through bypassing metabolic pathway.
MXPA02008082A (en) Pyridinylimidazoles.
MX2008012127A (en) Azolopyridin-3-one derivatives as inhibitors of endothelial lipase.
MX2007000789A (en) Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors.
MXPA02012272A (en) Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv.
IL164637D0 (en) Vaginal care compositions containing viable microorganisms
UA79447C2 (en) Indole derivates, pharmaceutical composition based thereon, process for their preparation (variants), intermediate compound
NZ571757A (en) Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
WO2005085234A3 (en) Bycyclic anthranilamide derivatives useful as insecticides
HK1065707A1 (en) 4--substituted nucleosides

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
LAPS Patent lapsed